Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Morphine for Skin Graft Pain
NCT00362219Phase 3Withdrawn
- Sponsor
- Rambam Health Care Campus
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of morphine hydrochloride in pain (4 arms), sponsored by Rambam Health Care Campus. Primary endpoint: Pain score in first 24 hours. Planned start Jan 2022; status: withdrawn.
02
Drugs
morphine hydrochloride
03
Conditions
pain
Beyond the preview
Go deeper on NCT00362219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362219.